Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2024 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Aloner who wrote (60)	4/13/2024 5:51:39 PM
From: technetium	Respond to of 194

I root for the Red Sox, and am quite familiar with the phrase, “Wait ‘til next year.”

To: Aloner who wrote (60)	4/13/2024 6:19:21 PM
From: technetium	Read Replies (1) \| Respond to of 194

aacr.org Abstracts: aacr.org It’s ASCO that used to refuse to allow abstracts to be released publicly, [but let their attendees sell them at a high price to people on Wall Street well in advance of the meeting,] all in the name of keeping their meeting at the cutting edge of the state of the art, as if oncologists wouldn’t show up to meet and greet one another if the abstracts were released early. I don’t know if they changed their policy. It’s difficult to believe that ASCO and AACR don’t know full well that the abstracts from their meetings can lead to major stock price swings for various small biotechs and even big pharma. One thing I noticed years ago was looking at the floor plan for the commercial layout from various companies that usually goes along with any major conference. If you think your company has something worth selling, or informing anyone about, you buy floor space. On the other hand, if you know your drug is a bust, there’s no reason to spend a dime on floor space, even if you’ve already committed to presenting a poster and want to speak to all and sundry that wander by in order to catch their attention and perhaps future funding.